Kazachstania turicensis CAU Y1706 and composition using same

Patent metadata

Field	Value
Publication number	US-12180459-B2
Application number	US-202017425079-A
Country	US
Kind code	B2
Filing date	Jan 23, 2020
Priority date	Jan 23, 2019
Publication date	Dec 31, 2024
Grant date	Dec 31, 2024

Abstract

The present invention relates to a novel Kazachstania turicensis CAU Y1706 and a composition using same, and more specifically, to a Kazachstania turicensis CAU Y1706 (Accession No.: KCTC13794BP) strain, and a pharmaceutical composition, a food composition, a cosmetic composition, and a probiotic composition for preventing or treating inflammatory diseases, comprising the strain or a culture thereof as an active ingredient.

First claim

What is claimed is:

1. A method for treating an inflammatory disease comprising administering to a subject in need thereof an effective amount of a composition comprising Kazachstania turicensis CAU Y1706 (accession number: KCTC13794BP) strain or a culture thereof as an active ingredient.

2. The method of claim 1 , wherein the Kazachstania turicensis CAU Y1706 (accession number: KCTC13794BP) has anti-inflammatory activity.

3. The method of claim 1 , wherein the Kazachstania turicensis CAU Y1706 (accession number: KCTC13794BP) has acid resistance or bile resistance.

4. The method of claim 1 , wherein the Kazachstania turicensis CAU Y1706 (accession number: KCTC13794BP) improves Th1/Th2 immune response imbalance.

5. The method of claim 1 , wherein the inflammatory disease is any one selected from the group consisting of acute or chronic organ transplant rejection, graft-versus-host disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory skin disease, multiple sclerosis, pancreatitis, trauma-induced shock, bronchial asthma, allergic rhinitis, allergic conjunctivitis, cystic fibrosis, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondyloarthropathy, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enteric spondylitis, juvenile arthritis, juvenile ankylosing spondylitis, reactive arthropathy, infectious arthritis, post-infectious arthritis, Lou Gehrig's disease, polyarteritis nodosa, hypersensitivity vasculitis, granulomatosis Lou Gehrig's disease, polymyalgia rheumatica, articular cell arteritis, calcium crystallization arthropathy, pseudo gout, non-articular rheumatism, bursitis, tendinitis, epicondylitis, neuropathic joint diseases (neuropathic joint disease or charcot joint), hemarthrosis, allergic purpura, hypertrophic osteoarthropathy, multicentral reticulocytoma, scoliosis, hemochromatosis, hemoglobinopathy, hyperproteinemia, hypogammaglobulinemia, familial Mediterranean fever, Behcet's disease, systemic lupus erythematosus, recurrent fever, sepsis, septic shock, acute respiratory distress syndrome, multiple organ failure, chronic obstructive pulmonary disease, rheumatoid arthritis, acute lung injury, broncho-pulmonary dysplasia, type 1 diabetes, type 2 diabetes, arteriosclerosis, Alzheimer's dementia, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, neonatal multisystem inflammatory disease, chronic infantile neurologic cutaneous articular syndrome, adult-onset Still's disease, contact dermatitis, hydatidiform mole, Pyogenic Arthritis, Pyoderma gangrenosum and Acne (PAPA) syndrome, hyperimmunoglobulin d syndrome, cryopyrin-associated periodic syndrome, keratitis, conjunctivitis, retinitis, retinal vasculitis, uveitis, blepharitis, dry eye, progressive systemic sclerosis, polymyositis, autoimmune encephalomyelitis, myasthenia gravis, polyarteritis nodosa and fibromyalgia syndrome.

6. The method of claim 5 , wherein the inflammatory skin disease is any one selected from the group consisting of psoriasis, atopic dermatitis, dermatitis eczema, contact dermatitis, seborrheic dermatitis, pneumoconiosis rosacea, lichen planus, vasculitis, pityriasis pilaris, cellulitis, folliculitis, pemphigus, bullous pemphigus, epidermal blistering, urticaria, angioedema, erythema and cutaneous eosinophilia.

7. A method for improving an inflammatory disease comprising administering to a subject in need thereof an effective amount of a composition comprising Kazachstania turicensis CAU Y1706 (accession number: KCTC13794BP) strain or a culture thereof as an active ingredient.

8. A method for improving an inflammatory disease comprising applying to a subject in need thereof an effective amount of a cosmetic composition comprising Kazachstania turicensis CAU Y1706 (accession number: KCTC13794BP) strain or a culture thereof as an active ingredient.

9. The method of claim 7 , wherein the composition is a food composition, probiotic composition, or an enteral composition.

10. A method of immunomodulation comprising administering to a subject in need thereof an effective amount of a composition comprising Kazachstania turicensis CAU Y1706 (accession number: KCTC13794BP) strain or a culture thereof as an active ingredient.

Assignees

• Univ Chung Ang Ind Acad Coop Found

Inventors

• Kim Won Yong
• Kim Jong Hwa
• Kim Ki Young
• Rungravee Kanjanasuntree

Classifications

• A61Q19/00

  Preparations for care of the skin · CPC title

• A61K36/06

  Fungi, e.g. yeasts · CPC title

• A61P17/00 Primary

  Drugs for dermatological disorders · CPC title

• A61K8/9728

  Fungi, e.g. yeasts · CPC title

• A23L31/15

  Extracts · CPC title